Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations

BRAF mutations occur in ~10% of colorectal cancer (CRC). While RAF inhibitor monotherapy is highly effective in BRAF-mutant melanoma, response rates in BRAF-mutant CRC are poor. Recent clinical trials of combined RAF/EGFR or RAF/MEK inhibition have produced improved efficacy, but patients ultimately...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Ahronian, Leanne G., Sennott, Erin M., Van Allen, Eliezer M., Wagle, Nikhil, Kwak, Eunice L., Faris, Jason E., Godfrey, Jason T., Nishimura, Koki, Lynch, Kerry D., Mermel, Craig H., Lockerman, Elizabeth L., Kalsy, Anuj, Gurski, Joseph M., Bahl, Samira, Anderka, Kristin, Green, Lisa M., Lennon, Niall J., Huynh, Tiffany G., Mino-Kenudson, Mari, Getz, Gad, Dias-Santagata, Dora, Iafrate, A. John, Engelman, Jeffrey A., Garraway, Levi A., Corcoran, Ryan B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390490/
https://ncbi.nlm.nih.gov/pubmed/25673644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-1518
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados